Start-Up Paradigm Raises $200 Million to Speed Up Drug Trials


New York-based Paradigm has raised a significant amount to simplify clinical trials. Its goal is ambitious, but its challenges are many, researchers say.

Previous Story

Sundance, Once a Hotbed for Film Deals, Tries to Find Its Footing

Next Story

Anthropic Said to Be Closing In on $300 Million in New A.I. Funding